Latest news
The Ruling That Cost Amarin Its $213.6M Drug Alex Tuch (I2wumZrvjY) - MshaleMshale · Mon, 10 Aug 2026 22:46:02 GMTAmarin Earnings Call: Cost Cuts, Cash Strength, Mixed Sales - TipRanksTipRanks · Sun, 02 Aug 2026 00:16:05 GMTAmarin (AMRN) Stock Hinges On Cash Flow As Revenue Retreat Deepens - simplywall.stsimplywall.st · Fri, 31 Jul 2026 00:40:46 GMTAmarin Q2 2026 Results: International VASCEPA Sales Surge 59%, Costs Cut 59%, and Positive Cash Flow Achieved - MinichartMinichart · Thu, 30 Jul 2026 01:43:00 GMTAmarin's Q2 Earnings Beat Estimates, Revenues Fall Short - TradingViewTradingView · Wed, 29 Jul 2026 16:17:00 GMTAmarin reports Q2 2026: $42.2M revenue, $14.99M gross profit, $7.7M net loss, positive cash flow - TradingViewTradingView · Wed, 29 Jul 2026 07:00:00 GMTAmarin (NASDAQ: AMRN) cuts Q2 2026 costs as cash rises to $314.6M - Stock TitanStock Titan · Wed, 29 Jul 2026 07:00:00 GMTAmarin's VASCEPA Demand Rises 59% Globally; U.S. Share Hits 48% - Stock TitanStock Titan · Wed, 29 Jul 2026 07:00:00 GMT